The board of Venus Medtech (Hangzhou) Inc. announced that Professor Martin B. Leon has been appointed as the global Principal Investigator ("PI") for the new generation of renal artery denervation ("RDN") innovative system developed by Renaly Ltd. ("Renaly"), controlling subsidiary. Meanwhile, he also serves as the director of Columbia Interventional Cardiovascular Care, director of the Cardiac Catheterization Laboratory, and the director of the Executive Board of the Columbia Structural Heart & Valve Center. In addition, he is also the founder and chairman of the global Transcatheter Cardiovascular Therapeutics ("TCT") conference. In the field of RDN, Professor Martin and his team have been serving as the PI for clinical trials for several innovative systems including Medtronic's Symplicity SpyralTM Renal Denervation System and ReCor Medical's ParadiseTM Ultrasonic Denervation System, both of which were awarded Breakthrough Device Designation by the U.S Food and Drug Administration in 2020. The new generation of RDN innovative system is developed by Renaly. Its exclusive Dual-Mode Ultrasound Technology (DMUT) Platform can realize non-contact continuous ablation treatment with real-time monitoring function, which significantly reduces the occurrence of various problems such as insufficient nerve ablation or vascular damage caused by uncontrollable ablation while achieving accurate and efficient ablation, in order to shift the treatment paradigm to more predictable outcomes and simplify the operation procedure flow to ultimately improve the safety and efficacy of ablation procedures.